Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 32, Number 9—September 2026
Dispatch
Serologic Evidence of Hantavirus Exposure in Humans, Italy, 2004–2018
Table 1
Antibody screening results determined by immunofluorescence assay in study of serologic evidence of hantavirus exposure in humans, Italy, 2004–2018
| Classification/patient group description | Sampling year | No. (%) patients |
||||
|---|---|---|---|---|---|---|
| Total | Hantavirus IgG positive |
LCMV IgG positive | ||||
| PUUV | DOBV | Combined | ||||
| Alcohol abuse |
2013–2016 (mostly 2013) |
28 (7.55) |
2 (7.14) |
1 (3.57) |
3 (10.71) |
0 |
| Liver diseases |
2004, 2009, 2012 (mostly 2012) |
177 (47.71) |
5 (2.82) |
11 (6.21) |
16 (9.04) |
4 (1.69) |
| HCV infections |
2018 |
30 (8.09) |
0 |
0 |
0 |
1 (3.33) |
| Renal diseases |
2006, 2007, 2018 |
110 (29.65) |
3 (2.72) |
3 (2.72) |
6 (5.45) |
5 (4.55) |
| Oral anticoagulant treatment |
2007 |
26 (7) |
1 (3.85) |
1 (3.85) |
2 (7.69) |
0 |
| Total | 371 (100) | 11 (2.96) | 16 (4.31) | 27 (7.28) | 10 (2.70) | |
*DOBV, Dobrava-Belgrade virus; HCV, hepatitis C virus; LCMV, lymphocytic choriomeningitis virus; PUUV, Puumala virus.
Page created: July 09, 2026
Page updated: July 09, 2026
Page reviewed: July 09, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.